Literature DB >> 11117964

HCV prevalence in pregnant women in the UK.

A E Ades1, S Parker, J Walker, W D Cubitt, R Jones.   

Abstract

The objective of the study was to assess the prevalence and epidemiology of hepatitis C virus (HCV) infection in pregnant women in the North Thames region, and in the UK in general. Demographic data were linked to neonatal samples prior to anonymization and testing by anti-HCV EIA, and with RIBA 3 confirmation. Risk factors for maternal infection were explored. Area-specific seroprevalence rates were multiplied into population sizes to estimate HCV prevalence in pregnant women in the UK. A total of 241/126,009 samples were confirmed anti-HCV positive, and a further 40 were indeterminate, representing a seroprevalence of 0.19-0.22%; 51% of maternal HCV infections were in UK-born women (71% of the population), and 22% in women from continental Europe (5% of the population). Among European-born women, HCV prevalence was associated with birth in continental Europe, partner not being notified at birth registration, partner born in a different region to the mother, and inner city residence. Four of the 241 anti-HCV positive samples (1.7%) were also anti-HIV-1 positive. It was estimated that each year an estimated 1150 out of 730,000 pregnancies in the UK would involve a woman infected with HCV (uncertainty range 660-1850), a prevalence of 0.16% (0.09-0.25%). On the basis of reported rates of mother-to-child transmission of HCV, this would represent approximately 70 paediatric HCV infections per year.

Entities:  

Mesh:

Year:  2000        PMID: 11117964      PMCID: PMC2869613          DOI: 10.1017/s0950268899004598

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

1.  Rapid screening for co-infection of HIV and HCV in pregnant women in Benin City, Edo State, Nigeria.

Authors:  M U Duru; H S A Aluyi; K C Anukam
Journal:  Afr Health Sci       Date:  2009-09       Impact factor: 0.927

Review 2.  Perinatal hepatitis C virus infection: diagnosis and management.

Authors:  S M Davison; G Mieli-Vergani; J Sira; D A Kelly
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

Review 3.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 4.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis.

Authors:  S J Hutchinson; D J Goldberg; M King; S O Cameron; L E Shaw; A Brown; J MacKenzie; K Wilson; L MacDonald
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

6.  Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Authors:  Irit Rosen; Michal Kori; Orly Eshach Adiv; Baruch Yerushalmi; Nataly Zion; Ron Shaoul
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

Review 7.  Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission.

Authors:  P G McIntyre; K Tosh; W McGuire
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

8.  Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women?

Authors:  Chloe Orkin; Anna Jeffery-Smith; Graham R Foster; C Y William Tong
Journal:  BMJ Open       Date:  2016-05-26       Impact factor: 2.692

9.  Hepatitis C virus seroprevalence in pregnant women delivering live-born infants in North Thames, England in 2012.

Authors:  M Cortina-Borja; D Williams; C S Peckham; H Bailey; C Thorne
Journal:  Epidemiol Infect       Date:  2015-07-16       Impact factor: 2.451

Review 10.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.